Hormonal contraception in women with polycystic ovary syndrome: choices, challenges, and noncontraceptive benefits

Anderson Sanches de Melo
Rosana Maria dos Reis
Rui Alberto Ferriani
Carolina Sales Vieira

Department of Gynecology and Obstetrics, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, São Paulo, Brazil

Abstract: Polycystic ovary syndrome (PCOS) is an endocrine disorder among women of reproductive age characterized by chronic anovulation and polycystic ovary morphology and/or hyperandrogenism. Management of clinical manifestations of PCOS, such as menstrual irregularities and hyperandrogenism symptoms, includes lifestyle changes and combined hormonal contraceptives (CHCs). CHCs contain estrogen that exerts antiandrogenic properties by triggering the hepatic synthesis of sex hormone-binding globulin that reduces the free testosterone levels. Moreover, the progestogen present in CHCs and in progestogen-only contraceptives suppresses luteinizing hormone secretion. In addition, some types of progestogens directly antagonize the effects of androgens on their receptor and also reduce the activity of the 5α reductase enzyme. However, PCOS is related to clinical and metabolic comorbidities that may limit the prescription of CHCs. Clinicians should be aware of risk factors, such as age, smoking, obesity, diabetes, systemic arterial hypertension, dyslipidemia, and a personal or family history, of a venous thromboembolic event or thrombophilia. This article reports a narrative review of the available evidence of the safety of hormonal contraceptives in women with PCOS. Considerations are made for the possible impact of hormonal contraceptives on endocrine, metabolic, and cardiovascular health.

Keywords: polycystic ovary syndrome, hormonal contraceptive, lipid metabolism, carbohydrate metabolism, hyperandrogenism, thrombosis

Introduction
Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder with prevalence rates ranging from 5% to 13.9% in women of reproductive age. Polycystic ovary syndrome (PCOS) is mainly characterized by chronic anovulation, polycystic ovary morphology, and hyperandrogenism. However, there is considerable interindividual variation in the presentation of diverse clinical and metabolic symptoms that vary across ethnic groups and geographic regions.

Together with lifestyle changes, combined hormonal contraceptives (CHCs) are the first-line management options for clinical manifestations of PCOS, specifically menstrual irregularity, hirsutism, and acne. CHCs contain an estrogen component (ethynylestradiol [EE], estradiol valerate, or estradiol) and a progestogen component that vary in terms of composition and affinity to receptors of other steroid hormones (mineralocorticoids, glucocorticoids, androgens, and estrogen). Both estrogen and progestogen contribute to management of the clinical manifestations of hyperandrogenism.
PCOS are associated with clinical and metabolic comorbidities that may limit the prescription of CHCs in women with PCOS. Common risk factors for cardiovascular diseases (CVDs), such as systemic arterial hypertension (SAH), obesity, dyslipidemia, metabolic syndrome (MeTS), and type 2 diabetes mellitus (DM2), can develop in women with PCOS by the fourth decade of life.\textsuperscript{5,10–12} According to the Medical Eligibility Criteria for Contraceptive Use of the World Health Organization (WHO), some of these comorbidities (MeTS, SAH, DM2 with vasculopathy, and dyslipidemia plus another risk factors) are considered to be category 3 (a condition where the theoretical or proven risks usually outweigh the advantages of using the method) or 4 (a condition which represents an unacceptable health risk if the contraceptive method is used) (Table 1). In both categories, progestogen-only contraceptives (POCs) are typically considered a safer option for women presenting with risk factors for CVD.\textsuperscript{13} In cases of presenting with contraindications to CHC, POCs or nonhormonal contraceptives\textsuperscript{13} can be coadministered with antiandrogen medication to control hyperandrogenism symptoms.\textsuperscript{14}

Because of the paucity of data about the impact of CHCs on cardiovascular and metabolic parameters in PCOS patients, most recommendations are based on studies involving ovulatory women. The objective of this narrative review is to present an evaluation of the evidence on available hormonal contraceptives, their noncontraceptive benefits, and adverse effects in women with PCOS, according to the Medical Eligibility Criteria for Contraceptive Use of the WHO.\textsuperscript{13} A specific focus of this review is considerations for endocrine, metabolic, and cardiovascular health of women with PCOS.

### Review criteria
The PubMed electronic bibliographic database was searched from January 1960 to September 2015 to identify reviews, clinical guidelines, observational, and interventional studies evaluating the effects of the use of any hormonal contraception in women or with or without diagnosed PCOS. Only published full-text articles in English were included. We prioritized the results of meta-analyses and guidelines/consensus.

The following search strategy was used: ((polycystic ovary syndrome) AND (hormonal contraceptive) AND (lipid metabolism)), ((polycystic ovary syndrome) AND (hormonal contraceptive) AND (carbohydrate metabolism OR insulin)), ((polycystic ovary syndrome) AND (hormonal contraceptive) AND (systemic arterial hypertension)), ((polycystic ovary syndrome) AND (hormonal contraceptive) AND (obesity)), ((polycystic ovary syndrome) AND (hormonal contraceptive) AND (thrombophilia)), ((polycystic ovary syndrome) AND (hormonal contraceptive) AND (mellitus diabetes type 2)), ((polycystic ovary syndrome) AND (hormonal contraceptive) AND (dyslipidemia)), and ((polycystic ovary syndrome) AND (hormonal contraceptive) AND (metabolic syndrome)).

The narrative synthesis of identified data was conducted. First, the benefits of CHCs on hyperandrogenism symptoms and endometrial cancer in women with PCOS are considered. Next, the six most important negative effects of hormonal contraceptives are considered in the context of their use in women with PCOS.

### Noncontraceptive benefits of hormonal contraception in women with PCOS

#### Management of hyperandrogenism symptoms

Hyperandrogenism is the most prominent diagnostic component of PCOS.\textsuperscript{3} Decrease in clinical manifestations of hyperandrogenism is considered not only to have esthetical benefits but also to contribute to a reduction of risk factors for metabolic disorders.\textsuperscript{4}

Evidence suggests that CHCs decrease hyperandrogenism symptoms by reducing production of androgens. More specifically, the estrogen component of CHCs has been shown to increase the hepatic synthesis of sex hormone-binding globulin (SHBG), subsequently reducing the free testosterone that can bind the androgen receptor.\textsuperscript{15} This antiandrogen effect is more prominent with the use of EE than with the use of natural estrogen.\textsuperscript{15} A systematic review of 42 experimental studies with meta-analysis demonstrated that independent of the type of progestogens present in combined oral contraceptives (COCs) containing 20–35 µg EE, the use of COCs was associated with a 61% reduction of free testosterone levels.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Eligibility criteria of the World Health Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Category</td>
<td>Eligibility</td>
</tr>
<tr>
<td>1</td>
<td>A condition for which there is no restriction for the use of the contraceptive method</td>
</tr>
<tr>
<td>2</td>
<td>A condition where the advantages of using the method generally outweigh the theoretical or proven risks</td>
</tr>
<tr>
<td>3</td>
<td>A condition where the theoretical or proven risks usually outweigh the advantages of using the method</td>
</tr>
<tr>
<td>4</td>
<td>A condition which represents an unacceptable health risk if the contraceptive method is used.</td>
</tr>
</tbody>
</table>

However, COCs containing low doses (20 µg) of EE or consisting of second-generation progestogens (levonorgestrel) had a smaller effect on the increase of SHBG compared to COCs containing higher EE doses or other progestogens (50% vs 150%–250% increase SHBG).

In addition to these antiandrogen properties, progestogen promotes negative feedback on the surge of luteinizing hormone, as a result reducing the ovarian androgen production. Some progestogens can directly antagonize the effects of androgens on the androgen receptor and also reduce the activity of the 5α reductase enzyme, which converts testosterone to dihydrotestosterone, the latter being a highly potent androgen. COCs containing cyproterone acetate have been shown to have a higher antiandrogen activity than desogestrel and drospirenone in long-term users (12 months or more), but not in short-/medium-term users (up to 6 months).

Based on this evidence, the Endocrine Society Clinical Practice Guideline, the American Society of Reproductive Medicine, and the European Society of Human Reproduction and Embryology have recommended the use of COCs as the initial pharmacological treatment of choice for women with PCOS, but the guidelines do not suggest any specific combination of compounds. The European Society of Endocrinology specifically recommends COCs containing cyproterone acetate for a more effective management of hyperandrogenism. However, in the presence of estrogen contraindication, drugs with an antiandrogen effect should be used in combination with effective contraceptives (nonhormonal methods or POCs). Similarly, the Androgen Excess and PCOS Society has established a protocol for the treatment of hirsutism in which the COCs of choice are those containing progestogens with a greater antiandrogen potential, such as cyproterone, chloromadinone, and drospirenone.

Nonoral methods containing EE have not been discussed in these clinical guidelines, possibly due to scarcity of evidence. However, these contraceptive methods can be expected to exert antiandrogen properties by reducing free testosterone and increasing SHBG. Since some POCs have the ability to inhibit luteinizing hormone secretion, POCs may also have some effect on the improvement of hyperandrogenism. In ovulatory women, the etonogestrel implant was shown to be associated with a reduction of testosterone and SHBG after 12 weeks of use. The effect of POCs in women with PCOS, however, still requires investigation. Based on the existing clinical guidelines, a possible flow diagram of eligibility of hormonal contraceptives for women with PCOS is presented in Figure 1.

Endometrial cancer
A systematic review with meta-analysis of eleven case–control studies concluded that compared to women without PCOS, women with PCOS are at three times higher risk for endometrial cancer (odds ratio [OR] 2.79, 95% confidence interval [95% CI] 1.31–5.95) at any age, but not for ovarian or breast cancer. While this estimate might have been overstated as a result of inclusion of studies that used self-reported diagnosis of PCOS and with possible selection biases related to failure to control for body mass index (BMI), overall PCOS presents a prominent risk factor for endometrial cancer. General population data show that hormonal contraceptive users have a lower incidence of endometrial cancer than nonusers. A prospective observational study is needed to confirm this effect of hormonal contraceptives in women with PCOS.

Choices and challenges
Systemic arterial hypertension
SAH can be found in women with PCOS, especially as one of the diagnostic criteria for MeTS. However, comorbidities detected in PCOS, such as obesity, dyslipidemia, and insulin resistance, can justify SAH independently of PCOS itself. In an attempt to exclude these possible confounding factors, Chen et al demonstrated a positive correlation of total testosterone levels and free androgen index with blood pressure. High blood pressure levels were also identified in the parents of women with PCOS compared to the parents of healthy women matched for age and BMI.

Endogenous estradiol can result in the vasodilation of blood vessels by increasing the production of nitric oxide and appropriate collagen synthesis, thus reducing arterial pressure. In turn, endogenous progesterone supports this hypotensive action by having an antimineralocorticoid
effect. However, EE that is present in most of CHCs, due to its greater potency compared to estradiol, elevates the production of the hepatic angiotensinogen, which causes an elevation of blood pressure via the rennin–angiotensin–aldosterone system, regardless of the route of administration.26 Despite the development of new progestogens, only drospirenone has the antimineralocorticoid activity of endogenous progesterone, regardless of the EE dose present in COCs.29–31

As a result, systolic arterial hypertension is regarded an adverse effect of COCs.32 Several studies have shown an association between hypertension and the use of COCs with a high EE dose, although an increased blood pressure was observed even with the use of monophasic pills containing 30 µg EE.33 In a cohort study, an increased relative risk of 1.8 (95% CI=1.5–2.3) to develop systolic arterial hypertension was observed in COC users compared to nonusers.34 In addition, higher diastolic arterial pressure levels and a poorer pressure control have been reported in hypertensive women using COCs compared to hypertensive nonusers, regardless of age, body weight, or hypertensive drugs used.35 A reduction in pressure levels of hypertensive women was detected ~6 months after the interruption of COC use.36

The negative effect of EE appears to be independent of the route of administration of CHCs since the hepatic activation promoted by EE occurs independently of the route of CHC administration.37 Within this context, POCs have the advantage of having no negative effect on blood pressure, thus representing a safe contraceptive method in women with PCOS.13

In conclusion, according to the eligibility criteria of the WHO, the use of CHCs is not indicated for women with hypertension with or without PCOS, regardless of the route of administration or estrogen type. If a woman with PCOS presents associated SAH, the eligible treatment methods are POCs or nonhormonal contraceptives. However, in women with severe SAH (≥160×100 mmHg) or with associated vasculopathy, the depot medroxyprogesterone acetate (DMPA) is category 3 and the CHCs are category 4 (Table 2).13

| Table 2 Medical eligibility criteria for hormonal contraceptive use in women with SAH |
|---------------------------------|----|----|----|----|----|----|
| Controlled SAH                  | 3  | 3  | 1  | 2  | 1  | 1  |
| Uncontrolled SAH (mmHg)         |    |    |    |    |    |    |
| 140–159×90–99                   | 3  | 3  | 1  | 2  | 1  | 1  |
| ≥160×100                        | 4  | 4  | 2  | 3  | 2  | 2  |


Abbreviations: CIC, combined injectable contraceptive; COC, combined oral contraceptive; DMPA, depot medroxyprogesterone acetate; ENG, etonogestrel; LNG, levonorgestrel; LNG-IUS, levonorgestrel-releasing intrauterine system; POP, progestogen-only pill; SAH, systemic arterial hypertension.

Lipid metabolism

Dyslipidemia is associated with PCOS independently of weight.38 Of the variables associated with lipid profile, CHCs have a greater negative impact on triglyceride (TG) levels, causing more than 40% of an increase in TG levels in women without PCOS and of up to 75% in women with PCOS regardless of the route of EE administration. In addition, women with PCOS who do not use CHCs may also show a reduction of high density lipoprotein (HDL)-cholesterol, whereas increases in total cholesterol and low density lipoprotein-cholesterol levels are less frequent.40

In general, EE administered by any route increases very low density lipoprotein-cholesterol and TG levels.40 Progestogens play a significant modulatory role in the elevation of TG and HDL-cholesterol levels promoted by estrogens.41 In contrast, the administration of POCs does not seem to interfere with the lipid profile.42 However, DMPA is associated with increased low density lipoprotein and reduced HDL levels, although this negative effect is transitory and does not persist 2 years after the discontinuation of this method.43

A meta-analysis has demonstrated that the use of COCs for at least 3 months was significantly associated with an increase in HDL and TG levels in women with PCOS, although these changes were not clinically significant.44 To the best of our knowledge, there is no information of the effect of POCs on the lipid profile of women with PCOS.

The 2009 Medical Eligibility Criteria of the WHO considered the use of combined contraceptive methods for women with hypertriglyceridemia as category 3 due to the increased risk of CVD and pancreatitis. However, a recent systematic review with meta-analysis, based on limited data from poor-quality observational studies, has demonstrated that women with known dyslipidemia using CHCs may be at increased risk for myocardial infarction (MI) and may experience a minimal increase in risk for arterial or venous thrombosis but the use of CHC was not associated with a high risk of pancreatitis.47 Based on this evidence, according to the 2015 version of the WHO Medical Eligibility Criteria for
Hormonal contraception and polycystic ovary syndrome

Contraceptive Use, women in reproductive age with known dyslipidemias without other known cardiovascular risk factors can generally use any hormonal contraceptive method. In the presence of one of these risk factors, all CHCs should be avoided. DMPA has been classified as the category 3 due its negative effect on HDL levels in women with dyslipidemia and cardiovascular risk factors (Table 3).

Carbohydrate metabolism and insulin sensitivity

PCOS is a risk factor for DM2. Approximately 30% of women with PCOS have reduced glucose tolerance and ~10% of them have DM2. For comparison, prevalence rates of reduced glucose tolerance and undiagnosed DM2 in healthy women aged 20–44 years are 7.8% and 1%, respectively.

Insulin resistance seems to play an important role in the physiopathology of PCOS. The first studies that evaluated the effect of COCs on glucose metabolism in healthy women showed a negative effect on glucose tolerance. However, these studies were conducted in the 1960s; at this time, high-dose COCs were used (EE doses of 50 µg or higher). A comprehensive systematic review with meta-analysis of observational studies has shown that the use of COCs for at least 3 months was not associated with negative effects on glucose metabolism as measured by the hyperinsulinemic euglycemic clamp, fasting glucose to insulin ratios, and homeostatic model assessments.

A systematic review and meta-analysis of 31 trials on the participation of CHCs in carbohydrate metabolism in women without DM2 has demonstrated that independent of the route of administration and estrogen type (EE or natural), CHCs have a limited effect on carbohydrate metabolism, and therefore no adverse effects for endocrine health. The authors, however, were unable to draw strong recommendations based on this evidence as the majority of studies compared different types of contraceptives, had small sample sizes, high lost-follow-up rates, poorly described methodologies, and failed to control for BMI.

In a systematic review with meta-analysis of four randomized controlled trials comparing COCs with metformin in PCOS, metformin was found to be superior in terms of reduction of fasting insulin, albeit the two treatments showed no significant difference in fasting glucose levels or the onset of DM2. To establish the safest option in terms of metabolic outcome of hormonal contraceptives, trials evaluating the long-term effects of these medications are needed.

In summary, evidence suggests that women with PCOS should use CHCs containing low EE doses (<50 µg) as these do not affect carbohydrate metabolism or pose a risk of developing DM2. According to the Medical Eligibility Criteria for Contraceptive Use of the WHO, CHCs can still be used by patients with associated PCOS and diabetes, regardless of insulin use. However, POCS or nonhormonal contraceptives should be used in the presence of associated vasculopathy (or diabetes of >20 years’ duration), except DMPA since this compound is associated with the reduction of HDL levels (Table 4).

Body weight

Many clinicians and users have observed weight gain during the use of hormonal contraception, with a consequent early

Table 3 Medical eligibility criteria for hormonal contraceptive use in women with dyslipidemia

<table>
<thead>
<tr>
<th>Dyslipidemia with no other risk factors</th>
<th>COC/RING/PATCH</th>
<th>CIC</th>
<th>POP</th>
<th>DMPA</th>
<th>ENG/LNG IMPLANTS</th>
<th>LNG-IUS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dyslipidemia with other risk factors</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>


Table 4 Medical eligibility criteria for hormonal contraceptive use in women with diabetes mellitus (DM) associated or not with vasculopathy

<table>
<thead>
<tr>
<th>DM (regardless of insulin use)</th>
<th>COC/RING/PATCH</th>
<th>CIC</th>
<th>POP</th>
<th>DMPA</th>
<th>ENG/LNG IMPLANTS</th>
<th>LNG-IUS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonvascular disease</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Nephropathy, retinopathy, neuropathy, or another vascular disease or diabetes of &gt;20 years duration</td>
<td>3/4</td>
<td>3/4</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

discontinuation of the method despite its efficacy or delay in its prescription. Several mechanisms have been proposed to the mechanisms underlying this observed impact of hormonal contraceptives on weight gain, but none of them has been fully confirmed. Specific research evidence on the association between CHCs and body weight in women with PCOS appears to be lacking entirely, but many studies have investigated effects of different hormonal contraceptives on body weight in healthy women. In a retrospective study on 2,138 women uninterruptedly using DMPA, the levonorgestrel-releasing intrauterine system (LNG-IUS), or the copper intrauterine device (Cu-IUD), 1 year follow-up all groups showed an increase in body weight, compared to baseline, with a mean weight gain of 1.3, 0.7, and 0.2 kg in the DMPA, LNG-IUS, and Cu-IUD groups, respectively (P<0.0001). After 10 years of use, the mean weight had risen by 6.6, 4.0, and 4.9 kg among the DMPA, LNG-IUS, and Cu-IUD users, respectively. DMPA users had gained more weight than the LNG-IUS (P=0.0197) and Cu-IUD users (P=0.0294). The authors concluded that users of hormonal and nonhormonal contraceptive methods gained a significant amount of weight over the years, but DMPA users gained more weight over a treatment period of up to 10 years than women using either the LNG-IUS or Cu-IUD.

A Cochrane review evaluated the relationship between various forms of POCs and their association with weight gain, albeit the presence of PCOS was not considered in the review. The authors have identified two studies that investigated weight gain in DMPA users compared to Cu-IUD users: while one study showed no significant difference, the other showed a statistically significant weight gain in the DMPA group at 1 year (mean difference [MD] =2.28 kg; 95% CI 1.79–2.77), 2 years (MD =2.71 kg; 95% CI 2.12–3.30), and 3 years (MD =3.17 kg; 95% CI 2.51–3.83), with this difference being significant only for patients with normal weight or overweight. Regarding body composition, the meta-analysis included two studies showing that DMPA users had a greater increase in body fat (%) (MD 11.00; 95% CI 2.64–19.36) and a greater decrease in lean body mass (%) (MD =−4.00; 95% CI −6.93 to −1.07) compared to users of other hormonal methods. Another study, included in the meta-analysis, demonstrated that the LNG-IUS group showed an increase in body fat mass (2.5% vs −1.3%, respectively; P=0.029) and a reduction of percent change in lean body mass (−1.4% vs 1.0%, respectively; P=0.027) in relation to Cu-IUD users, although no significant change in body weight was observed between groups. Despite these considerations, the authors concluded that there is limited evidence of weight gain when using POCs. Except for DPMA, mean gain was <2 kg up to 12 months for most studies, but the weight change of the POC group generally did not differ significantly from groups using another contraceptives.

A group of Danish authors recently carried out two randomized controlled trials which demonstrated that the use of metformin alone or in combination with COCs was associated with weight loss and improved body composition compared with the use of COCs alone. One of these studies revealed a small but significant weight gain in the group taking COCs alone, leading the authors to a conclusion that metformin use with or without COCs should be considered as an alternative for the treatment of PCOS to avoid weight gain with COCs alone.

Overall, the authors of a systematic review with meta-analysis of as many as 49 trials on the link between combination contraceptives and weight change in healthy women were unable to confidently determine the effect of combination contraceptives on weight. They have suggested a need for trials with a placebo or nonhormonal group to control for other factors, including changes in weight over time. The WHO, however, considers any hormonal contraceptive method to be adequate for obese women who have no other associated risk factors for CVD. Due to the absence of evidence in women with PCOS, data for the general population have been applied to draw recommendations to women with PCOS (Table 5).

### Metabolic syndrome

PCOS is commonly associated with MeTS, which is diagnosed by the presence of at least three of the following criteria: waist circumference ≥88 cm, fasting glycemia ≥100 mg/dL, TGs ≥150 mg/dL, HDL ≤50 mg/dL, and blood pressure ≥130/85 mmHg. Prevalence rates of MeTS in women with PCOS vary according to the region under study. For example, prevalence rates in the US range from 43% to 46%. To

| COC/RING/ CIC POP DMPA ENG/LNG LNG-IUS PATCH IMPLANTS |
|------------|------------|-------------|-------------|
| Obesity    | 2          | 2           | 1           |

Abbreviations: CIC, combined injectable contraceptive; COC, combined oral contraceptive; DMPA, depot medroxyprogesterone acetate; ENG, etonogestrel; LNG, levonorgestrel; LNG-IUS, levonorgestrel-releasing intrauterine system; POP, progestogen-only pill.
compare, three to six times lower prevalence rates were reported in Italy (5%–17.3%) and even four to 20 times lower prevalence rates were reported for women in People’s Republic of China (2.3%–12.2%). In Brazil, prevalence rates of MeTS range from 33.3% to 45.4%, depending on the PCOS phenotype. The observed differences are likely to be related to factors inherent to a specific population under the study. Especially regarding PCOS phenotypes, diagnostic criteria, diet, and lifestyle may interfere with the prevalence of this syndrome. Overall, regardless of the diagnostic criterion of PCOS, the prevalence of MeTS in women with PCOS is at least twice as high as the prevalence population without PCOS.

MeTS is associated with an increased risk of arterial thrombosis events since it was linked to the development of atherosclerosis. In addition, it has been reported that MeTS is associated with a twofold increase in the risk of venous thromboembolism (VTE).

The presence of MeTS in the general population is associated with a twofold increase in the risk of developing CVD. Since women with PCOS are at an increased risk of MeTS and cardiovascular events, a hormonal contraceptive method should be chosen with caution in women with PCOS associated with MeTS. According to the WHO, only POCs (except for DMPA) and nonhormonal contraceptives are suitable for women with MeTS that carries multiple risk factors for CVD. The DMPA has unfavorable metabolic effects, such as a reduction of HDL levels, which limit its use in situations of an increased cardiovascular risk (Table 6).

### Arterial and venous thrombosis

CVDs include MI, angina, cerebrovascular accidents (CVA), and peripheral vascular disease (ie, peripheral arterial disease, venous thrombosis, and deep vein thrombosis). In women with PCOS, those who were taking COCs had a twofold increased risk of VTE (characterized by deep vein thrombosis and pulmonary embolism) and those not taking oral contraceptives had a 1.5-fold increased risk.

A systematic review of observational studies demonstrated that women with PCOS have a twofold increased risk of CVD than the population without PCOS (relative risk 2.02; 95% CI 1.47–2.76), a risk that remained ~1.5 times higher after adjusting for BMI (relative risk 1.55; 95% CI 1.27–1.89). In a systematic review and a meta-analysis of five studies, the risk of nonfatal stroke was twofold higher among climacteric women with a history of PCOS compared to the population without PCOS (OR 1.94; 95% CI 1.19–3.17). However, there was no significant difference for MI and/or mortality due to CVD.

A recent Cochrane systematic review with meta-analysis, inclusive of nonrandomized trials, showed that the risk of MI or CVA was only increased in women using COCs containing ≥50 µg of estrogen, with the prescription of COCs with <50 µg of estrogen showing to be safe regarding the risk of MI (OR 0.9, 95% CI 0.8–1.0) or CVA (OR 1.0, 95% CI 0.9–1.1).

A Danish historical cohort study included 1,626,158 women aged 15–49 years without a history of CVD or cancer. The authors concluded that the absolute risks of CVA and MI associated with the use of COCs were low. This risk was increased by a factor of 0.9–1.7 with COCs that included EE at a dose of 20 µg and by a factor of 1.3–2.3 with those that included EE at a dose of 30–40 µg, with no differences in risk according to progestin type.

Regarding VTE, a Danish historical cohort study conducted on 8,010,290 women aged 15–49 years without a history of thrombotic disease demonstrated that, compared to nonusers of CHCs, the relative risk of confirmed VTE in users of COCs containing 30–40 µg EE varied according to the type of progestogen present. After adjusting for time of use, the rate of confirmed VTE was 2.2 (1.7–3.0) for users of COCs with desogestrel, 2.1 (1.6–2.8) for users of COCs with gestodene, and 2.1 (1.6–2.8) for users of COCs with drospirenone compared to users of COCs with levonorgestrel. The risk of confirmed VTE was not increased with the use of POCs. The authors concluded that users of COCs with desogestrel, gestodene, or drospirenone were at least at twice the risk of VTE compared with users of COCs with levonorgestrel. However, this result was not confirmed in a prospective, controlled, noninterventional cohort study conducted in the US and in six European countries. In this study, the use of COCs containing drospirenone was associated

### Table 6 Medical eligibility criteria for hormonal contraceptive use in women with MeTS

<table>
<thead>
<tr>
<th>COC/patch</th>
<th>CIC</th>
<th>POP</th>
<th>DMPA</th>
<th>ENG/LNG implants</th>
</tr>
</thead>
<tbody>
<tr>
<td>MeTS</td>
<td>3/4</td>
<td>3/4</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>

**Note:** Reprinted from Medical eligibility criteria for contraceptive use, Fifth edition, World Health Organization, 1–267. Copyright 2015. Available from: http://www.who.int/reproductivehealth/publications/family_planning/MEC-5/en/ Abbreviations: CIC, combined injectable contraceptive; COC, combined oral contraceptive; DMPA, depot medroxyprogesterone acetate; ENG, etonogestrel; LNG, levonorgestrel; LNG-IUS, levonorgestrel-releasing intrauterine system; MeTS, metabolic syndrome; POP, progestogen-only pill.
with similar risk of venous and arterial thromboembolism compared to COCs without drospirenone or COCs containing levonorgestrel.76

Another Cochrane systematic review and meta-analysis concluded that all COCs were associated with an increased risk of VTE, but the size of the effect depended both on the progestogen used and the dose of EE.77 The authors have estimated that the relative risk of VTE for COCs with 30–35 µg ethinylestradiol and gestodene, desogestrel, cyproterone acetate, or drospirenone was similar and ~50%–80% higher than for COCs with levonorgestrel. On this basis, the COCs with lower dose of EE with levonorgestrel would be safer in order to reduce the risk of VTE.77 However, this result should be considered with caution since the review was inclusive of both chronic users (several years) of COCs containing levonorgestrel and recent users of COCs containing other progestogens. This is an important limitation because the first year of CHC use involves a higher risk of VTE.75–77 Despite the difference in thrombogenic potential according to the antiandrogen effect of progestogens, the absolute risk for VTE is small among healthy women in reproductive age.

Another historical Danish cohort study assessed the risk of VTE in 1,626,158 users of nonoral products compared to the standard reference COC with levonorgestrel and 30–40 µg estrogen or nonusers aged 15–49 years. The authors concluded that users of transdermal patches or vaginal rings have a 7.9 and 6.5 times increased risk of VTE compared to the standard reference COC with levonorgestrel and 30–40 µg estrogen or nonusers aged 15–49 years. The relative risk of VTE for COCs with a BMI <25 kg/m² was 1.29–5.53) for DMPA users, compared to nonusers. The relative risk for VTE was 0.90 (95% CI: 0.57–1.45) for POC users, 0.61 (95% CI: 0.24–1.53) for LNG-IUS users, and 2.67 (95% CI: 1.29–5.53) for DMPA users, compared to nonusers. The authors concluded that the use of POC was not associated with an increased risk of VTE compared with nonusers of hormonal contraception and that the relationship between DMPA and VTE needs to be further investigated.78

Although it is safe to prescribe any hormonal contraceptive to obese women with no other associated risk factors, obesity alone can involve approximately a 24-fold increase in the risk of VTE among COC users compared to nonusers of COCs with a BMI <25 kg/m².79 For this reason, although obesity is not a contraindication for CHC use, caution should be taken in the association of CHC use and obesity.

It is important to point out that screening for thrombophilia before prescribing a hormonal contraceptive is not recommended.80 Table 7 presents the WHO’s Medical Eligibility Criteria for Contraceptive Use in women with arterial and venous thrombosis.13 The main clinical conditions related to prescription of hormonal contraceptives in women with PCOS are summarized in Table 8.

**Conclusion**

CHCs are the first-choice treatment options for PCOS. This review suggests one of the important reasons for their use is evident reduction of hyperandrogenism symptoms and endometrial cancer risk. However, metabolic disorders may be aggravated or even triggered by the use of some CHCs.

Many clinical guideline recommendations for hormonal contraceptive use in women with PCOS are based on studies in women without PCOS. Consequently, clinicians should still evaluate each patient individually and consider the presence of risk factors, such as age, smoking, obesity, diabetes, SAH, dyslipidemia, and a personal or family history of a venous thromboembolic event or thrombophilia. Table 8 summarizes the recommendation of hormonal contraceptive use in the presence of comorbidities. When the use of estrogen is contraindicated for the patient or when multiple risk factors for CVD are present or intolerance of EE occurs, the use of POCs or nonhormonal contraceptives is recommended. If these methods do not adequately control the symptoms of hyperandrogenism, an alternative is to combine a POC or a nonhormonal method with an antiandrogen medication, such as spironolactone, cyproterone, or finasteride.

**Table 7 Medical eligibility criteria for hormonal contraceptive use in women with a history of arterial or venous thrombosis**

<table>
<thead>
<tr>
<th>COC/RING/PATCH</th>
<th>CIC</th>
<th>POP</th>
<th>DMPA</th>
<th>ENG/LNG IMPLANTS</th>
<th>LNG-IUS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personal history of DVT/PE or thrombophilia</td>
<td>4</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>History of stroke or ischemic heart disease</td>
<td>4</td>
<td>4</td>
<td>2/3*</td>
<td>3</td>
<td>2/3*</td>
</tr>
</tbody>
</table>

Notes: Reprinted from Medical eligibility criteria for contraceptive use, Fifth edition, World Health Organization, 1–267. Copyright 2015. Available from: http://www.who.int/reproductivehealth/publications/family_planning/MEC-5/en/.13 *If the ischemic episode occurred during the use of POC (POP, implant, and LNG-IUS), the method is defined as category 3; if the patient has a personal history of ischemic heart disease and the event occurred before the use of POC, the method is defined as category 2 and can be started.

Abbreviations: CIC, combined injectable contraceptive; COC, combined oral contraceptive; DMPA, depot medroxyprogesterone acetate; DVT/PE, deep venous thrombosis/pulmonary embolism; ENG, etonogestrel; LNG, levonorgestrel; LNG-IUS, levonorgestrel-releasing intrauterine system; POP, progestogen-only contraceptive; POC, progestogen-only pill.
Table 8 Summary of medical eligibility criteria for hormonal contraceptive use in women with comorbidities related to polycystic ovary syndrome

<table>
<thead>
<tr>
<th></th>
<th>COC/RING/PATCH</th>
<th>CIC</th>
<th>POP</th>
<th>DMPA</th>
<th>ENG/LNG IMPLANTS</th>
<th>LNG-IUS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controlled SAH</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Uncontrolled SAH (mmHg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>140–159 &amp; 90–99</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>≥160 &amp; ≥100</td>
<td>4</td>
<td>4</td>
<td>2</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>MeTS</td>
<td>4</td>
<td>4</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Dyslipidemia with no other risk factors</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Dyslipidemia with other risk factors</td>
<td>3/4</td>
<td>3/4</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>DM (regardless of insulin use)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonvascular disease</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Nephropathy, retinopathy, neuropathy, or diabetes of &gt;20 years duration</td>
<td>3/4</td>
<td>3/4</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Personal history of DVT/PE or thrombophilia</td>
<td>4</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>History of stroke or ischemic heart disease</td>
<td>4</td>
<td>4</td>
<td>2/3*</td>
<td>3</td>
<td>2/3*</td>
<td>2/3*</td>
</tr>
</tbody>
</table>


*If the ischemic episode occurred during the use of POC (POP, implant, and LNG-IUS), the method is defined as category 3; if the patient has a personal history of ischemic heart disease and the event occurred before the use of POC, the method is defined as category 2 and can be started.

Abbreviations: CIC, combined injectable contraceptive; COC, combined oral contraceptive; DM, diabetes mellitus; DMPA, depot medroxyprogesterone acetate; DVT/PE, deep venous thrombosis/pulmonary embolism; ENG, etonogestrel; LNG, levonorgestrel; LNG-IUS, levonorgestrel-releasing intrauterine system; MeTS, metabolic syndrome; POC, progestogen-only contraceptive; POP, progestogen-only pill; SAH, systemic arterial hypertension; POC, progestogen-only contraceptive.

Disclosure

The authors report no conflicts of interest in this work.

References


44. Barkfeldt J, Virkkanen U, Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 microg/day) or levonorgestrel (30 microg/day) on lipid metabolism. *Contraception.* 2001;64(5):295–299.


Hormonal contraception and polycystic ovary syndrome


